NIDA-CTO-0011
Division
HEAL Study
Investigator(s)
Title
Double-Blind, Placebo-Controlled, Dose Response Trial Of Ondansetron For The Treatment Of Methamphetamine Dependence
Short Description
This study was designed to be a preliminary assessment of the efficacy and safety of 3-wide range doses of ondansetron (0.25, 1.0 and 4.0 mg taken orally twice per day) to reduce methamphetamine use in subjects with methamphetamine dependence and to determine the optimal dose of ondansetron.
Release Date
Jan 15, 2019
Description
The primary objective of this study is to conduct a preliminary assessment of the possible efficacy of ondansetron to reduce methamphetamine use in outpatients with methamphetamine dependence. The hypothesis is that ondansetron treatment compared to placebo will decrease the weekly proportion of methamphetamine positive urines. The results of this study will be used to design subsequent larger studies to confirm the efficacy of ondansetron. This study is also intended to gather preliminary information on biological or psychosocial characteristics of patients who may show better ondansetron treatment responsiveness.
Keywords
Assessments
Accessibility Notice
Please note that the supplementary documents may not be fully Section 508 compliant. Please contact us for assistance.